Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.

International journal of hematology - 1 Jan 2012

Karimi Mehran, Haghpanah Sezaneh, Farhadi Ali, Yavarian Majid

Abstract excerpt

We evaluated the clinical responses to hydroxyurea (HU), adverse effects, and β-globin gene variants in a large series of β-thalassemic patients over a 13-year period in Iran. The patients (n = 232) were divided into two groups: transfusion-dependent β-thalassemia patients 2 years of age and older (n = 126; Group 1), and β-thalassemia intermedia (βTI) patients without any history of blood transfusion or with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites
Share to beta-Globins
Share to beta-Thalassemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Hydroxyurea

Share to Site-Specific DNA-Methyltransferase (Adenine-Specific)

Share to Transfusion Reaction

Source

Identifiers

PMID: 22180324
DOI: 10.1007/s12185-011-0985-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.PMID 22180324Read ↗

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.Semantic proximity Read ↗

Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.Semantic proximity Read ↗

Drug repurposing: Hydroxyurea therapy improves the transfusion-free interval in HbE/beta-thalassemia–major patients with Xmn1 polymorphismSemantic proximity Read ↗

Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.Semantic proximity Read ↗

The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.Semantic proximity Read ↗

Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.Semantic proximity Read ↗

Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the XmnI Polymorphism.Semantic proximity Read ↗

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?Semantic proximity Read ↗

Successful Use of Hydroxyurea in β-Thalassemia MajorSemantic proximity Read ↗

Clinical efficacy of thalidomide for various genotypes of beta thalassemiaSemantic proximity Read ↗

Relationship Between Some Single-nucleotide Polymorphism and Response to Hydroxyurea Therapy in Iranian Patients With β-Thalassemia Intermedia.Semantic proximity Read ↗

Response to hydroxyurea therapy in beta-thalassemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.